These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26358365)

  • 1. The delicate balance of macrophages in colorectal cancer; their role in tumour development and therapeutic potential.
    Braster R; Bögels M; Beelen RH; van Egmond M
    Immunobiology; 2017 Jan; 222(1):21-30. PubMed ID: 26358365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophages in human colorectal cancer are pro-inflammatory and prime T cells towards an anti-tumour type-1 inflammatory response.
    Ong SM; Tan YC; Beretta O; Jiang D; Yeap WH; Tai JJ; Wong WC; Yang H; Schwarz H; Lim KH; Koh PK; Ling KL; Wong SC
    Eur J Immunol; 2012 Jan; 42(1):89-100. PubMed ID: 22009685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of mesenchymal stem cells by macrophages promotes tumor progression through immune suppressive effects.
    Jia XH; Feng GW; Wang ZL; Du Y; Shen C; Hui H; Peng D; Li ZJ; Kong DL; Tian J
    Oncotarget; 2016 Apr; 7(15):20934-44. PubMed ID: 26988913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy.
    Li TT; Ogino S; Qian ZR
    World J Gastroenterol; 2014 Dec; 20(47):17699-708. PubMed ID: 25548469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of macrophages on ulcerative colitis-associated carcinogenesis].
    Wang W; Zhou Y; Li X; Shen S
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Jun; 37(6):637-41. PubMed ID: 22772418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor macrophages protective and pathogenic roles in cancer development.
    Qualls JE; Murray PJ
    Curr Top Dev Biol; 2011; 94():309-28. PubMed ID: 21295691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy.
    Sica A; Schioppa T; Mantovani A; Allavena P
    Eur J Cancer; 2006 Apr; 42(6):717-27. PubMed ID: 16520032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The IL-23 to IL-17 cascade inflammation-related cancers.
    Wang K; Karin M
    Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S87-90. PubMed ID: 26457610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory Responses during Tumour Initiation: From Zebrafish Transgenic Models of Cancer to Evidence from Mouse and Man.
    Elliot A; Myllymäki H; Feng Y
    Cells; 2020 Apr; 9(4):. PubMed ID: 32325966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Th1 cytokines are more effective than Th2 cytokines at licensing anti-tumour functions in CD40-activated human macrophages in vitro.
    Luheshi N; Davies G; Poon E; Wiggins K; McCourt M; Legg J
    Eur J Immunol; 2014 Jan; 44(1):162-72. PubMed ID: 24114634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The complement system in cancer: Ambivalence between tumour destruction and promotion.
    Mamidi S; Höne S; Kirschfink M
    Immunobiology; 2017 Jan; 222(1):45-54. PubMed ID: 26686908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inability of tumour cells to elicit the respiratory burst in cytotoxic, activated macrophages.
    Bryant SM; Hill HR
    Immunology; 1982 Mar; 45(3):577-85. PubMed ID: 6277777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.
    Pander J; Heusinkveld M; van der Straaten T; Jordanova ES; Baak-Pablo R; Gelderblom H; Morreau H; van der Burg SH; Guchelaar HJ; van Hall T
    Clin Cancer Res; 2011 Sep; 17(17):5668-73. PubMed ID: 21788356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation in sporadic colorectal cancer.
    Moossavi S; Bishehsari F
    Arch Iran Med; 2012 Mar; 15(3):166-70. PubMed ID: 22369306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-associated macrophages as treatment targets in oncology.
    Mantovani A; Marchesi F; Malesci A; Laghi L; Allavena P
    Nat Rev Clin Oncol; 2017 Jul; 14(7):399-416. PubMed ID: 28117416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance.
    Allavena P; Sica A; Garlanda C; Mantovani A
    Immunol Rev; 2008 Apr; 222():155-61. PubMed ID: 18364000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in colorectal cancer.
    Le DT
    Clin Adv Hematol Oncol; 2018 Jan; 16(1):22-24. PubMed ID: 29741500
    [No Abstract]   [Full Text] [Related]  

  • 19. Macrophages: modulators of breast cancer progression.
    Lin EY; Pollard JW
    Novartis Found Symp; 2004; 256():158-68; discussion 168-72, 259-69. PubMed ID: 15027489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current concepts in immunotherapy for the treatment of colorectal cancer.
    Indar A; Maxwell-Armstrong CA; Durrant LG; Carmichael J; Scholefield JH
    J R Coll Surg Edinb; 2002 Apr; 47(2):458-74. PubMed ID: 12018689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.